Dyne Therapeutics falls on revised timelines for genetic disorder therapy
Shares of therapy developer Dyne Therapeutics DYN.O fall 19.03% to $11.20
Co revises timelines for data updates and submission for its genetic disorder therapy DYNE-101 after meeting with FDA
DYNE-101 is being studied for the treatment of myotonic dystrophy type 1, a genetic disorder causing progressive muscle weakness and wasting
Co revises main goal in the registration expansion cohort to change from baseline in middle finger myotonia, a symptom which causes delayed muscle relaxation, as measured by video hand opening test at 6 months, compared to placebo
Data from the trial is now expected in mid-2026, compared to first half of 2026 expected previously
Also pushes submission seeking accelerated approval to late 2026 from H1 2026
Stock down ~47% YTD
Related Articles
Silver Faces Sixth Consecutive Year of Supply Deficit, How Much Upside Is Left in 2026?
TradingKey - According to the 2026 Silver Market Outlook recently released by the Silver Institute, the current robust performance of the silver market remains supported by solid fundamentals. The report indicates that the global silver market is expected to face a structural supply-demand imbalance
Retail Trading Hub Robinhood Sinks Again, Slumping Over 7% After Hours, Signaling Lack of Interest in Crypto?
TradingKey - Robinhood (HOOD) reported a 34% decline in fourth-quarter net profit to $605 million, with total revenue of $1.28 billion missing Wall Street expectations.
After $20B Debt Sale, Google’s Rare 100-Year Bond Sparks Scrutiny: Has AI Drained the Tech Giant’s Coffers?
TradingKey - According to a Financial Times report, Google parent Alphabet (GOOG)(GOOGL) is planning to issue bonds denominated in British pounds and Swiss francs, which may include the first 100-year GBP bond of this century.
SpaceX IPO Approaching: Will EchoStar Be a Good Buy in 2026?
TradingKey - Today, EchoStar (SATS) is a hybrid story around legacy consumer communications and a high-profile private space play. As a result of its merger with DISH, the company offers satellite TV services and the wireless brand Boost Mobile, in addition to spectrum assets and wholesale network a
U.S. January Nonfarm Payrolls Preview: Likely to Beat Expectations, but with Limited Impact on US Stocks
TradingKey - Against the backdrop of the U.S. economy demonstrating robust resilience and the coordinated easing of monetary and fiscal policies, the nonfarm payrolls data are likely to beat the market consensus expectations.
